2,6-Dimethylphenylhydrazine hydrochloride

We are 2,6-Dimethylphenylhydrazine hydrochloride CAS:2538-61-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,6-Dimethylphenylhydrazine hydrochloride
CAS.NO:2538-61-6
Synonyms:2,6-Dimethylphenylhydrazine hydrochloride
(2,6-dimethylphenyl)hydrazinium chloride
(2,6-Dimethylphenyl)hydrazine hydrochloride
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 219.4±29.0 °C at 760 mmHg
Molecular Formula C8H12N2
Molecular Weight 136.194
Flash Point 98.0±27.9 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.607
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Oxadixyl(CAS:77732-09-3).

2,6-Dimethylphenylhydrazine hydrochloride


Related News: CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.6-(chloromethyl)-11H-benzo[c][1]benzazepine CAS:21535-44-4 The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.(3Z) -1- (2,6-diclorofenil) -3 – [(2,3-dihidroxipropilamino) metilideno] indol-2-ona CAS:172371-96-9 The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.2,3-Difluorobenzotrifluoride CAS:64248-59-5 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).

Related Products
Product Name
(3R,4R)-3,4-Dimethyl-4-(3-Hydroxyphenyl)Piperidine View Details
3-chloro-4-[(3-fluorophenyl)methoxy]aniline View Details
4-(Difluoromethoxy)benzenesulfonamide View Details
Benzyl (1-cyano-1-methylethyl)carbamate manufacturer 4-Amino-2-(trifluoromethyl)benzonitrile manufacturer 1-Bromo-6-phenylpyrene manufacturer (2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoic acid manufacturer 2-(4-hydroxyphenyl)-1-benzothiophen-6-ol manufacturer